Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

OABI

OmniAb Inc

Nov 03 • 04:00PM ET

1.48

-0.07 -4.52 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IWN SCHA VTWO VHT DFAT IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	28.76%	Shs Outstand	122.70M	Perf Week	-6.92%
Market Cap	213.05M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	0.29%	Shs Float	102.56M	Perf Month	-9.20%
Enterprise Value	193.21M	PEG	-	EPS next Q	-0.14	Inst Own	38.07%	Short Float	5.83%	Perf Quarter	-27.45%
Income	-63.52M	P/S	9.25	EPS this Y	4.92%	Inst Trans	-13.07%	Short Ratio	11.35	Perf Half Y	-11.90%
Sales	23.03M	P/B	0.69	EPS next Y	27.87%	ROA	-20.07%	Short Interest	5.98M	Perf YTD	-58.19%
Book/sh	2.14	P/C	5.12	EPS next 5Y	18.52%	ROE	-22.84%	52W High	4.87 -69.61%	Perf Year	-62.91%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-22.68%	52W Low	1.22 21.31%	Perf 3Y	-82.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	15.37%	Volatility	5.42% 6.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8.39	EPS Y/Y TTM	2.24%	Oper. Margin	-301.33%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.77	Sales Y/Y TTM	6.05%	Profit Margin	-275.83%	RSI (14)	39.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.77	EPS Q/Q	-11.31%	SMA20	-9.02%	Beta	0.17	Target Price	8.50
Payout	-	Debt/Eq	0.08	Sales Q/Q	-48.82%	SMA50	-8.53%	Rel Volume	0.76	Prev Close	1.55
Employees	114	LT Debt/Eq	0.07	Earnings	Nov 04 AMC	SMA200	-29.79%	Avg Volume	527.01K	Price	1.48
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.81% -26.94%	Trades		Volume	405,178	Change	-4.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
08:00AM	Loading…
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
05:40PM	Loading…
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
04:05PM	Loading…
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM
Berkman Charles S	Chief Legal Officer	Dec 09 '24	Sale	4.13	8,022	33,131	323,385	Dec 10 04:47 PM
FOEHR MATTHEW W	President and CEO	Dec 09 '24	Sale	4.13	13,634	56,308	3,714,447	Dec 10 04:44 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 09 '24	Sale	4.13	23,871	98,587	200,661	Dec 10 04:41 PM
GUSTAFSON KURT A	Officer	Dec 09 '24	Proposed Sale	4.13	23,871	98,476		Dec 09 08:49 PM
FOEHR MATTHEW W	Officer	Dec 09 '24	Proposed Sale	4.13	13,634	56,245		Dec 09 08:45 PM
Berkman Charles S	Officer	Dec 09 '24	Proposed Sale	4.13	8,022	33,094		Dec 09 08:41 PM
FOEHR MATTHEW W	President and CEO	Nov 25 '24	Option Exercise	3.73	99,434	370,702	3,698,600	Nov 26 04:41 PM

Open in Screener

LGND

Ligand Pharmaceuticals, Inc

Nov 03 • 04:00PM ET

191.24

-0.07 -0.04 %

Healthcare • Biotechnology • USA • NASD

LGND Ligand Pharmaceuticals, Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR VTI IWM VB VBR VXF SPSM IWN SCHA IJT

Index	RUT	P/E	-	EPS (ttm)	-4.00	Insider Own	2.52%	Shs Outstand	19.41M	Perf Week	0.67%
Market Cap	3.75B	Forward P/E	24.59	EPS next Y	7.78	Insider Trans	-0.67%	Shs Float	19.10M	Perf Month	5.66%
Enterprise Value	3.51B	PEG	-	EPS next Q	1.93	Inst Own	99.80%	Short Float	6.18%	Perf Quarter	41.50%
Income	-75.86M	P/S	19.98	EPS this Y	21.14%	Inst Trans	2.96%	Short Ratio	5.26	Perf Half Y	79.82%
Sales	187.58M	P/B	4.48	EPS next Y	11.83%	ROA	-8.36%	Short Interest	1.18M	Perf YTD	78.48%
Book/sh	42.68	P/C	15.30	EPS next 5Y	17.03%	ROE	-9.46%	52W High	194.44 -1.65%	Perf Year	74.16%
Cash/sh	12.50	P/FCF	70.42	EPS past 3/5Y	- -	ROIC	-9.11%	52W Low	93.58 104.36%	Perf 3Y	244.89%
Dividend Est.	-	EV/EBITDA	154.15	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	75.44%	Volatility	3.82% 2.98%	Perf 5Y	243.89%
Dividend TTM	-	EV/Sales	18.70	EPS Y/Y TTM	-264.26%	Oper. Margin	-7.62%	ATR (14)	5.71	Perf 10Y	227.15%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	5.21	Sales Y/Y TTM	40.54%	Profit Margin	-40.44%	RSI (14)	66.66	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.45	EPS Q/Q	108.45%	SMA20	3.42%	Beta	1.03	Target Price	194.43
Payout	-	Debt/Eq	0.01	Sales Q/Q	14.68%	SMA50	9.33%	Rel Volume	1.21	Prev Close	191.31
Employees	68	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	45.66%	Avg Volume	224.63K	Price	191.24
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.57% 8.57%	Trades		Volume	268,953	Change	-0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169

Show Previous Ratings

Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
04:00PM	Loading…
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
02:00PM	Loading…
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
09:35AM	Loading…
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
KOZARICH JOHN W	Director	Jan 17 '25	Option Exercise	52.30	2,406	125,834	46,181	Jun 02 08:05 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM
Espinoza Octavio	Chief Financial Officer	Dec 23 '24	Sale	116.37	2,104	244,850	20,647	Dec 26 08:32 PM
Espinoza Octavio	Officer	Dec 23 '24	Proposed Sale	116.37	2,104	244,851		Dec 23 08:19 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Option Exercise	52.30	2,406	125,834	31,921	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Sale	123.65	2,406	297,502	29,515	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 26 '24	Proposed Sale	119.19	2,406	286,771		Nov 27 04:44 PM
Korenberg Matthew E	Officer	Nov 11 '24	Proposed Sale	120.33	32,183	3,872,684		Nov 12 10:25 AM

Open in Screener

TECH

Bio-Techne Corp

Nov 03 • 04:00PM ET

61.26

-1.31 -2.09 %

Healthcare • Biotechnology • USA • NASD

Peers: TMO DHR ILMN A BIO QGEN NEO MTD

| Held by: VTI VOO VB RSP IVV SPY VBK XLV IBB IWR

Index	S&P 500	P/E	135.08	EPS (ttm)	0.45	Insider Own	1.16%	Shs Outstand	154.97M	Perf Week	-4.65%
Market Cap	9.54B	Forward P/E	27.30	EPS next Y	2.24	Insider Trans	-1.92%	Shs Float	153.89M	Perf Month	-2.68%
Enterprise Value	9.82B	PEG	12.02	EPS next Q	0.42	Inst Own	102.57%	Short Float	4.51%	Perf Quarter	12.12%
Income	73.37M	P/S	7.82	EPS this Y	4.44%	Inst Trans	-2.63%	Short Ratio	3.02	Perf Half Y	23.01%
Sales	1.22B	P/B	4.95	EPS next Y	11.89%	ROA	2.73%	Short Interest	6.94M	Perf YTD	-14.95%
Book/sh	12.38	P/C	58.81	EPS next 5Y	11.24%	ROE	3.68%	52W High	80.80 -24.18%	Perf Year	-19.42%
Cash/sh	1.04	P/FCF	37.18	EPS past 3/5Y	-34.80% -20.58%	ROIC	3.12%	52W Low	46.01 33.14%	Perf 3Y	-17.15%
Dividend Est.	0.32 (0.52%)	EV/EBITDA	26.08	Sales past 3/5Y	3.33% 10.55%	Gross Margin	66.44%	Volatility	3.20% 3.33%	Perf 5Y	-7.95%
Dividend TTM	0.32 (0.52%)	EV/Sales	8.05	EPS Y/Y TTM	-56.70%	Oper. Margin	21.86%	ATR (14)	2.06	Perf 10Y	156.32%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	2.38	Sales Y/Y TTM	5.23%	Profit Margin	6.02%	RSI (14)	51.87	Recom	1.68
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	3.46	EPS Q/Q	-145.25%	SMA20	-0.96%	Beta	1.47	Target Price	67.83
Payout	69.67%	Debt/Eq	0.23	Sales Q/Q	3.55%	SMA50	6.77%	Rel Volume	0.82	Prev Close	62.57
Employees	3100	LT Debt/Eq	0.22	Earnings	Nov 05 BMO	SMA200	7.96%	Avg Volume	2.30M	Price	61.26
IPO	Feb 09, 1989	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.13% 0.75%	Trades		Volume	1,878,641	Change	-2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$73
Aug-21-25	Upgrade	Citigroup	Neutral → Buy	$70
Jul-22-25	Resumed	Stephens	Overweight	$65
Jul-09-25	Initiated	TD Cowen	Buy	$65
May-30-25	Initiated	Wells Fargo	Overweight	$59
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform	$75
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral	$88 → $68
May-22-24	Downgrade	Citigroup	Buy → Neutral	$85
Feb-08-24	Initiated	Scotiabank	Sector Outperform	$80
Feb-02-24	Downgrade	Stifel	Buy → Hold	$65
Dec-07-23	Initiated	UBS	Buy	$80
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$90
Dec-14-22	Initiated	Deutsche Bank	Buy	$100
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$81.25 → $100
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$89
Aug-25-22	Initiated	Credit Suisse	Outperform	$465
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight	$370
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$600

Show Previous Ratings

Nov-03-25 10:17PM	What To Expect From Bio-Techne's (TECH) Q3 Earnings (StockStory)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Sonoma Biotherapeutics (PR Newswire)
Oct-31-25 03:21PM	Why Bio-Techne (TECH) Stock Is Up Today (StockStory)
Oct-30-25 07:27PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
06:30AM	Loading…
Oct-28-25 06:30AM	Bio-Techne Launches ProximityScope Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research (PR Newswire)
Oct-23-25 06:56PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
07:54AM	Bio-Techne Q1 Earnings Preview: What's in Store for the Stock? (Zacks)
07:00AM	ScaleReady Announces multiple G-Rex Grants have been awarded to leading investigators at Children's National Hospital (PR Newswire)
Oct-16-25 12:04AM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Oct-15-25 09:00AM	Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents (Business Wire)
07:00AM	Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results (PR Newswire)
Oct-14-25 11:40AM	GMAB or TECH: Which Is the Better Value Stock Right Now? (Zacks)
08:48AM	Earnings Preview: What to Expect From Bio-Techne's Report (Barchart)
Oct-09-25 07:00AM	Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 (PR Newswire)
08:18AM	Loading…
Oct-08-25 08:18AM	Should You Continue to Hold Bio-Techne Stock in Your Portfolio? (Zacks)
Oct-03-25 04:16PM	S&P 500 Stocks: These 5 Lead As Index Hits Record High (Investor's Business Daily)
Sep-30-25 04:00PM	Bio-Techne (TECH) Shares Skyrocket, What You Need To Know (StockStory) +6.51% +7.71%
Sep-29-25 08:22AM	Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions (Zacks)
Sep-26-25 06:30AM	Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications (PR Newswire)
Sep-24-25 07:28AM	BioTechne (TECH) Fell Over the Industry's Uncertain Funding Environment (Insider Monkey)
07:15AM	Is Bio-Techne Stock Underperforming the Dow? (Barchart)
06:59AM	Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report (PR Newswire)
Sep-19-25 09:31AM	Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? (Zacks)
Sep-16-25 11:31PM	Research Tools & Consumables Stocks Q2 Highlights: Bio-Techne (NASDAQ:TECH) (StockStory)
Sep-15-25 09:28AM	Here's Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne's (TECH) Long-Term Growth Profile (Insider Monkey)
Sep-10-25 03:11PM	Why Bio-Techne (TECH) Stock Is Down Today (StockStory) -5.98%
Sep-09-25 04:05PM	CONMED Corporation Adds Kim Kelderman to its Board of Directors (Business Wire)
07:00AM	ScaleReady Awards G-Rex Grants to Support Cell and Gene Therapy Manufacturing in California (PR Newswire)
Sep-02-25 02:26PM	Why Bio-Techne (TECH) Shares Are Sliding Today (StockStory)
07:00AM	Loading…
Aug-27-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Aug-22-25 03:40PM	Bio-Techne, 10x Genomics, Lumen, EPAM, and ASGN Shares Are Soaring, What You Need To Know (StockStory) +5.72%
Aug-21-25 09:36AM	CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 07:57AM	Bio-Techne Stock: Analyst Estimates & Ratings (Barchart)
Aug-14-25 07:00AM	ScaleReady Announces Award of a G-Rex Grant to the Gates Institute's Translational Sciences Laboratory (PR Newswire)
Aug-13-25 01:35AM	The 5 Most Interesting Analyst Questions From Bio-Techne's Q2 Earnings Call (StockStory)
Aug-12-25 03:17AM	TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty (StockStory) +5.34%
Aug-11-25 02:56PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Aug-06-25 01:20PM	Why Bio-Techne (TECH) Shares Are Plunging Today (StockStory) -8.73%
09:31AM	Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations (StockStory)
09:30AM	Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings (Zacks)
09:05AM	Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls (Zacks)
07:50AM	Techne (TECH) Beats Q4 Earnings and Revenue Estimates (Zacks)
06:30AM	Bio-Techne Releases Fourth Quarter Fiscal 2025 Results (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Aug-05-25 04:30PM	Bio-Techne Announces Exosome Diagnostics Divestiture (PR Newswire)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Sidra Medicine (PR Newswire)
Aug-04-25 11:19PM	Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow (StockStory)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Aug-01-25 08:13AM	Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending (Insider Monkey)
07:46AM	Bio-Techne Corporation (TECH) Slid on Rise in Investors' Concerns (Insider Monkey)
Jul-31-25 07:00AM	ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering (PR Newswire) -5.16%
Jul-30-25 12:03AM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Jul-28-25 02:07AM	Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen (Insider Monkey)
Jul-24-25 04:07PM	Bio-Techne Corporation (TECH): A Bull Case Theory (Insider Monkey) +5.71%
Jul-22-25 02:05PM	Bio-Techne (TECH) Stock Is Up, What You Need To Know (StockStory) +5.67%
Jul-18-25 01:03AM	Bio-Technes Quarterly Earnings Preview: What You Need to Know (Barchart)
Jul-17-25 07:00AM	Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results (PR Newswire)
Jul-16-25 11:40AM	INCY or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Jul-15-25 10:09AM	Here's Headwaters Capital Management's Investment Thesis for Bio-Techne (TECH) (Insider Monkey)
09:03AM	Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology (Business Wire)
07:00AM	Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection (PR Newswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
Jul-09-25 01:33AM	5 Revealing Analyst Questions From Bio-Techne's Q1 Earnings Call (StockStory)
Jun-30-25 08:49AM	Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock (Zacks)
Jun-25-25 04:46PM	Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development (Insider Monkey)
08:44AM	Is Bio-Techne Stock Underperforming the Nasdaq? (Barchart)
Jun-24-25 07:00AM	Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development (PR Newswire)
Jun-10-25 01:15PM	TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts (StockStory)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Immuneel Therapeutics (PR Newswire)
Jun-06-25 04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
11:31AM	Why Is Techne (TECH) Down 3% Since Last Earnings Report? (Zacks)
Jun-02-25 11:33PM	Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 (StockStory)
May-30-25 12:47AM	Bio-Techne Corporation (TECH): A Bull Case Theory (Insider Monkey)
May-29-25 08:47AM	Is Bio-Techne Stock the Right Pick for Your Portfolio Now? (Zacks)
07:00AM	Bio-Techne to Present at Investor Conferences (PR Newswire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -7.27%
11:00AM	What Makes Bio-Techne Corporation (TECH) a Compelling Addition? (Insider Monkey)
07:00AM	ScaleReady awards multiple G-Rex Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) (PR Newswire)
May-12-25 07:00AM	Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 (PR Newswire) +7.93%
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-08-25 09:30AM	Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing (PR Newswire)
07:00AM	Bio-Techne to Present at the BofA Securities 2025 Health Care Conference (PR Newswire)
03:16AM	Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... (GuruFocus.com)
01:44AM	Q3 2025 Bio-Techne Corp Earnings Call (Thomson Reuters StreetEvents)
May-07-25 04:09PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
10:40AM	Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance (Seeking Alpha)
10:38AM	Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript (Seeking Alpha)
10:05AM	Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket (Zacks)
09:54AM	Bio Techne (TECH) Fell on Negative Funding Environment (Insider Monkey)
09:30AM	Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:34AM	Is the Options Market Predicting a Spike in BioTechne Stock? (Zacks)
07:40AM	Techne (TECH) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:30AM	BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM (PR Newswire)
May-06-25 07:00AM	ScaleReady awards a $300,000 G-Rex Grant to A2 Biotherapeutics, Inc. (PR Newswire)
May-05-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline (Zacks)
May-02-25 07:54AM	Should You Hold Bio-Techne Corp. (TECH) For the Long Term? (Insider Monkey)
May-01-25 08:25AM	Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nusse Roeland	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,599	Aug 27 04:10 PM
Nusse Roeland	Director	Aug 25 '25	Sale	56.36	17,040	960,388	44,559	Aug 27 04:10 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,903	Aug 27 04:09 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Sale	56.21	17,040	957,818	44,863	Aug 27 04:09 PM
ROELAND NUSSE	Director	Aug 25 '25	Proposed Sale	56.36	17,040	960,388		Aug 25 04:05 PM
ROBERT V. BAUMGARTNER4731 BONI	Director	Aug 25 '25	Proposed Sale	56.21	17,040	957,849		Aug 25 04:04 PM
Hippel James	CFO	Aug 15 '25	Option Exercise	0.00	4,010	0	131,809	Aug 19 05:38 PM
Herr Amy E.	Director	Aug 15 '25	Option Exercise	0.00	279	0	2,255	Aug 19 05:29 PM
Kelderman Kim	Chief Executive Officer	Aug 15 '25	Option Exercise	0.00	8,543	0	55,273	Aug 19 05:28 PM
Bohnen Shane	SVP - General Counsel	Aug 15 '25	Option Exercise	0.00	1,718	0	4,912	Aug 19 05:28 PM
McManus Matthew	President - Diag & Spatial Bio	Aug 15 '25	Option Exercise	0.00	2,637	0	5,615	Aug 19 05:28 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Aug 15 '25	Option Exercise	0.00	2,623	0	15,915	Aug 19 05:27 PM
HIGGINS JOHN L	Director	Aug 07 '25	Option Exercise	21.84	5,040	110,074	65,236	Aug 11 07:06 PM
Hippel James	CFO	Jul 29 '25	Option Exercise	44.33	168,620	7,474,925	275,230	Jul 31 04:28 PM
Kelderman Kim	Chief Executive Officer	Jul 22 '25	Option Exercise	44.33	48,176	2,135,642	90,379	Jul 24 04:26 PM
Kelderman Kim	Chief Executive Officer	Jul 15 '25	Option Exercise	44.33	36,132	1,601,732	75,136	Jul 17 05:04 PM
Herr Amy E.	Director	Jun 09 '25	Option Exercise	44.33	1,280	56,742	3,256	Jun 11 04:20 PM
Herr Amy E.	Director	Jun 09 '25	Sale	49.77	1,280	63,705	1,976	Jun 11 04:20 PM
JOSHUA MOLHO	Officer	Jun 09 '25	Proposed Sale	49.77	1,280	63,705		Jun 09 04:19 PM
HIGGINS JOHN L	Director	May 01 '25	Option Exercise	21.84	12,000	262,080	60,196	May 05 04:18 PM
Bohnen Shane	SVP - General Counsel	Apr 03 '25	Option Exercise	0.00	2,260	0	3,941	Apr 07 04:25 PM
Herr Amy E.	Director	Feb 14 '25	Option Exercise	44.33	1,976	87,596	3,836	Feb 18 04:49 PM
Herr Amy E.	Director	Feb 14 '25	Sale	65.96	1,860	122,691	1,976	Feb 18 04:49 PM
JOSHUA MOLHO	Domestic Partner of Director	Feb 14 '25	Proposed Sale	65.96	1,860	122,691		Feb 14 04:08 PM
McManus Matthew	President - DGS	Feb 01 '25	Option Exercise	0.00	4,620	0	4,620	Feb 04 05:31 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Feb 01 '25	Option Exercise	0.00	3,320	0	14,401	Feb 04 05:27 PM
Kelderman Kim	Chief Executive Officer	Jan 27 '25	Option Exercise	37.70	13,392	504,878	52,396	Jan 29 04:35 PM
Kelderman Kim	Chief Executive Officer	Jan 27 '25	Sale	77.29	13,392	1,035,013	39,004	Jan 29 04:35 PM
KIM KELDERMAN	Director	Jan 27 '25	Proposed Sale	77.05	13,392	1,031,854		Jan 27 04:24 PM

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals, Inc

TECH

Bio-Techne Corp

Upgrade your FINVIZ experience